Gunderson Dettmer Boston partner and co-chair of the firm's Life Science practice group, Tim Ehrlich, is quoted in BioPharma's article on the biotechnology sector's notable resurgence in initial public offerings in 2024. 

Tim spoke on how the biotech Metagenomi's efforts to go public were being watched by industry observers as a test of whether IPOs were open to earlier-stage companies. "'To really see momentum, we need to see an expansion of the opportunity for companies,' he said, so startups nearing human testing also have a shot."

Read the full article here.